These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 7793878)

  • 21. Mersacidin, a new antibiotic from Bacillus. In vitro and in vivo antibacterial activity.
    Chatterjee S; Chatterjee DK; Jani RH; Blumbach J; Ganguli BN; Klesel N; Limbert M; Seibert G
    J Antibiot (Tokyo); 1992 Jun; 45(6):839-45. PubMed ID: 1500348
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Interaction of type A lantibiotics with undecaprenol-bound cell envelope precursors.
    Müller A; Ulm H; Reder-Christ K; Sahl HG; Schneider T
    Microb Drug Resist; 2012 Jun; 18(3):261-70. PubMed ID: 22432708
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Activity of mersacidin, a novel peptide, compared with that of vancomycin, teicoplanin, and daptomycin.
    Niu WW; Neu HC
    Antimicrob Agents Chemother; 1991 May; 35(5):998-1000. PubMed ID: 1649577
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Molecular mechanism of inhibition of biosynthesis of peptidoglycan of bacterial cell walls by antibiotics].
    Torbochkina LI
    Antibiotiki; 1970 May; 15(5):465-76. PubMed ID: 4915727
    [No Abstract]   [Full Text] [Related]  

  • 25. Combination of antibiotic mechanisms in lantibiotics.
    Hoffmann A; Pag U; Wiedemann I; Sahl HG
    Farmaco; 2002 Aug; 57(8):685-91. PubMed ID: 12361237
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of the single regulator MrsR1 and the two-component system MrsR2/K2 in the regulation of mersacidin production and immunity.
    Guder A; Schmitter T; Wiedemann I; Sahl HG; Bierbaum G
    Appl Environ Microbiol; 2002 Jan; 68(1):106-13. PubMed ID: 11772616
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibition of peptidoglycan biosynthesis in vancomycin-susceptible and -resistant bacteria by a semisynthetic glycopeptide antibiotic.
    Allen NE; Hobbs JN; Nicas TI
    Antimicrob Agents Chemother; 1996 Oct; 40(10):2356-62. PubMed ID: 8891144
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mersacidin, a new antibiotic from Bacillus. Fermentation, isolation, purification and chemical characterization.
    Chatterjee S; Chatterjee S; Lad SJ; Phansalkar MS; Rupp RH; Ganguli BN; Fehlhaber HW; Kogler H
    J Antibiot (Tokyo); 1992 Jun; 45(6):832-8. PubMed ID: 1500347
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mode of action of glycine on the biosynthesis of peptidoglycan.
    Hammes W; Schleifer KH; Kandler O
    J Bacteriol; 1973 Nov; 116(2):1029-53. PubMed ID: 4200845
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antibiotic Effects on Methicillin-Resistant Staphylococcus aureus Cytoplasmic Peptidoglycan Intermediate Levels and Evidence for Potential Metabolite Level Regulatory Loops.
    Vemula H; Ayon NJ; Burton A; Gutheil WG
    Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28320719
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vancomycin derivatives that inhibit peptidoglycan biosynthesis without binding D-Ala-D-Ala.
    Ge M; Chen Z; Onishi HR; Kohler J; Silver LL; Kerns R; Fukuzawa S; Thompson C; Kahne D
    Science; 1999 Apr; 284(5413):507-11. PubMed ID: 10205063
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chemistry and biology of the ramoplanin family of peptide antibiotics.
    McCafferty DG; Cudic P; Frankel BA; Barkallah S; Kruger RG; Li W
    Biopolymers; 2002; 66(4):261-84. PubMed ID: 12491539
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibition of peptidoglycan synthesis by the antibiotic diumycin A.
    Lugtenberg EJ; Hellings JA; van de Berg GJ
    Antimicrob Agents Chemother; 1972 Dec; 2(6):485-91. PubMed ID: 4670441
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The flavoprotein MrsD catalyzes the oxidative decarboxylation reaction involved in formation of the peptidoglycan biosynthesis inhibitor mersacidin.
    Majer F; Schmid DG; Altena K; Bierbaum G; Kupke T
    J Bacteriol; 2002 Mar; 184(5):1234-43. PubMed ID: 11844751
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of Staphylococcus aureus Cell Wall Biosynthesis by Desleucyl-Oritavancin: a Quantitative Peptidoglycan Composition Analysis by Mass Spectrometry.
    Chang JD; Foster EE; Thadani AN; Ramirez AJ; Kim SJ
    J Bacteriol; 2017 Aug; 199(15):. PubMed ID: 28507244
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mode of action of lipid II-targeting lantibiotics.
    Bauer R; Dicks LM
    Int J Food Microbiol; 2005 May; 101(2):201-16. PubMed ID: 15862882
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chlorobiphenyl-desleucyl-vancomycin inhibits the transglycosylation process required for peptidoglycan synthesis in bacteria in the absence of dipeptide binding.
    Goldman RC; Baizman ER; Longley CB; Branstrom AA
    FEMS Microbiol Lett; 2000 Feb; 183(2):209-14. PubMed ID: 10675585
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expression of the lantibiotic mersacidin in Bacillus amyloliquefaciens FZB42.
    Herzner AM; Dischinger J; Szekat C; Josten M; Schmitz S; Yakéléba A; Reinartz R; Jansen A; Sahl HG; Piel J; Bierbaum G
    PLoS One; 2011; 6(7):e22389. PubMed ID: 21811596
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The lantibiotic NAI-107 binds to bactoprenol-bound cell wall precursors and impairs membrane functions.
    Münch D; Müller A; Schneider T; Kohl B; Wenzel M; Bandow JE; Maffioli S; Sosio M; Donadio S; Wimmer R; Sahl HG
    J Biol Chem; 2014 Apr; 289(17):12063-12076. PubMed ID: 24627484
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lipid II-based antimicrobial activity of the lantibiotic plantaricin C.
    Wiedemann I; Böttiger T; Bonelli RR; Schneider T; Sahl HG; Martínez B
    Appl Environ Microbiol; 2006 Apr; 72(4):2809-14. PubMed ID: 16597986
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.